Pharmacokinetics and Efficacy of Plant-Derived Nanomedicines for Chronic Pain

DOI: https://doi.org/10.63345/ijrmp.org.v10.i6.3

Disha Patel

Vadodara, Gujarat, India

Abstract

Chronic pain remains a major public health challenge, often refractory to conventional treatments. Recently, plant-derived nanomedicines have emerged as promising candidates for managing chronic pain due to their potential to improve bioavailability, reduce side effects, and target specific tissues. This study investigates the pharmacokinetic properties and therapeutic efficacy of several plant-based nanoformulations in preclinical models of chronic pain. We synthesized and characterized nanoparticles loaded with active phytochemicals known for their analgesic properties. Pharmacokinetic parameters were determined following oral and intravenous administration in rodent models, with the area under the curve, half-life, and tissue distribution serving as key metrics. In parallel, the analgesic efficacy was evaluated using validated behavioral assays and pain scales, comparing treated groups to standard analgesic regimens. A survey of clinicians and patients regarding the perceived benefits and potential barriers to nanomedicine adoption was also conducted. Statistical analyses, including regression and survival analyses, were performed to ensure robust interpretation of the data. The findings suggest that plant-derived nanomedicines not only improve pharmacokinetic profiles but also provide enhanced pain relief with fewer side effects compared to traditional treatments. These promising results lay the groundwork for future clinical studies and indicate that nanotechnology may represent a significant advancement in the treatment of chronic pain.

Keywords

Nanomedicine; Chronic Pain; Pharmacokinetics; Plant-derived; Efficacy; Analgesia; Preclinical.

References

• https://www.google.com/url?sa=i&url=https%3A%2F%2Fwww.frontiersin.org%2Fjournals%2Fpublic-health%2Farticles%2F10.3389%2Ffpubh.2021.779328%2Ffull&psig=AOvVaw2-fW_88XCvtNYew–1JV6j&ust=1741277712648000&source=images&cd=vfe&opi=89978449&ved=0CBQQjRxqFwoTCLim9aCw84sDFQAAAAAdAAAAABAE
• https://www.google.com/url?sa=i&url=https%3A%2F%2Fwww.researchgate.net%2Ffigure%2FNanomedicine-surgery-as-an-interdisciplinary-field-of-science-and-nanotechnology_fig2_347964883&psig=AOvVaw3AQfVjysoqlFwzlb2Imt7w&ust=1741278604026000&source=images&cd=vfe&opi=89978449&ved=0CBQQjRxqFwoTCLi54sau84sDFQAAAAAdAAAAABAZ
• Anderson, K., & Lee, J. (2020). Future directions in nanomedicine for chronic pain management. Future Medicinal Chemistry, 12(1), 15–27.
• Brown, R., & Evans, P. (2015). Nanoparticle encapsulation for enhanced efficacy in chronic pain: A preclinical evaluation. The Journal of Pain, 16(9), 1015–1022.
• Chen, X., Li, W., & Zhao, Y. (2017). Lipid-based nanocarriers for improving the bioavailability of plant-derived compounds. Journal of Controlled Release, 260, 119–130.
• Choi, S., Kim, H., & Park, J. (2015). Nanoparticle systems for enhanced delivery of natural analgesics. Journal of Nanotechnology in Medicine, 6(2), 95–104.
• Davis, M., & Thomas, A. (2018). Targeted delivery in nanomedicine for pain management: Current strategies and future prospects. Advanced Drug Delivery Reviews, 129, 1–12.
• Fischer, P., Müller, D., & Schneider, R. (2018). Biocompatibility and safety aspects of nanoparticle-based therapies in pain management. Journal of Nanobiotechnology, 16, 45–52.
• Gonzalez, M., Rivera, F., & Torres, E. (2018). Evaluation of nanoparticle formulations in preclinical pain models. Journal of Pain Management, 11(4), 301–310.
• Gupta, A., & Saxena, P. (2018). Advances in nanomedicine for chronic pain: A review of current trends. Journal of Pain Research, 11, 342–356.
• Hernandez, R., Martinez, L., & Delgado, J. (2019). Clinical perspectives on plant-derived nanomedicines for chronic pain. Pain Physician, 22(3), 267–278.
• Kumar, S., & Singh, V. (2019). Plant-derived therapeutics in pain management: Challenges and prospects. Phytotherapy Research, 33(5), 1234–1246.
• Lee, H., Jung, S., & Kim, Y. (2016). Enhancing the bioavailability of natural products via nanoparticle technology. International Journal of Pharmaceutics, 510(1), 1–10.
• Li, Y., Zhang, Q., & Zhao, F. (2016). Nanotechnology in natural product delivery: Strategies to improve bioavailability and efficacy. Current Medicinal Chemistry, 23(12), 1431–1440.
• Martinez, J., Gomez, P., & Rivera, M. (2017). Nanoparticle-mediated delivery of phytochemicals for effective pain relief. Journal of Biomedical Nanotechnology, 13(7), 1074–1083.
• Patel, S., Desai, R., & Mehta, N. (2016). Nanoparticle-based drug delivery systems in chronic pain management: An overview. Journal of Drug Delivery Science and Technology, 31, 74–80.
• Rahman, M., & Hossain, M. (2017). The role of nanoparticles in enhancing the pharmacokinetics of natural compounds. Drug Development and Industrial Pharmacy, 43(10), 1611–1618.
• Rodriguez, F., & Gomez, L. (2018). Nanomedicine strategies for chronic pain: Preclinical studies and future challenges. European Journal of Pain, 22(10), 1845–1853.
• Singh, D., & Kumar, A. (2019). Advances in nanoformulations of plant-derived drugs for pain management. Nanomedicine, 14(5), 573–584.
• Smith, J., & Patel, R. (2015). Nanoparticle delivery systems: An overview of current methodologies and applications. Nanomedicine: Nanotechnology, Biology and Medicine, 11(3), 789–797.
• Wang, Y., Chen, L., & Liu, X. (2019). Pharmacokinetic modulation of plant extracts using nanocarriers. European Journal of Pharmaceutical Sciences, 133, 43–50.
• Zhang, L., Sun, J., & Zhao, X. (2017). Pharmacokinetics of curcumin nanoparticles in inflammatory pain models. Journal of Nanoscience and Nanotechnology, 17(3), 1234–1240.